Literature DB >> 24685075

Prevalence of venous thromboembolic events and diagnostic performance of the wells score and revised geneva scores for pulmonary embolism in patients with interstitial lung disease: a prospective study.

Qun Luo1, Jiaxing Xie1, Qian Han1, Chunli Tang1, Xiaobo Chen1, Lulu Wu1, Rongchang Chen2.   

Abstract

BACKGROUND: To determine the prevalence of venous thromboembolism (VTE) in patients with connective tissue disease-related interstitial lung diseases (CTD-ILD) and idiopathic interstitial pneumonia (IIP) and to further evaluate associated risk factors. To also examine the diagnostic performance of the Wells score and the revised Geneva scores for diagnosing pulmonary embolism (PE) in ILD patients.
METHOD: Fifty-seven patients with CTD-ILD and IIP were prospectively enrolled. Plasma D-dimer was measured by ELISA. Deep-vein thrombosis (DVT) was examined by venous ultrasonography and PE by computed tomography pulmonary angiography. PE prevalence was further assessed by the Wells score and the revised Geneva score.
RESULTS: VTE was diagnosed in 15 (26.3%, 15/57) patients. Bivariate analysis revealed that dyspnoea (OR 3.750, 95%CI 1.095-12.842, P=0.035), lower extremity oedema (OR 8.667, 95%CI1.814-41.408, P=0.007), palpitations (OR 4.75, 95%CI1.073-21.032, P=0.040), and positive D-dimer (OR 5.087, 95%CI 1.015-25.485, P=0.048) were associated with VTE. Using the Wells Score, 46 (80.70%), eight (14.4%) and three (5.26%) patients had a low, intermediate and high probability of PE, respectively, with seven (15.22%), three (37.5%) and two (66.67%) of the respective cases confirmed. By the revised Geneva score, 23 (40.35%), 32 (56.14%) and two (3.51%) patients had a low, intermediate and high probability of PE, respectively, with two (8.70%), nine (28.13%) and one (50.00%) of the respective cases confirmed. The AUC for the Wells score and the revised Geneva score was 0.720±0.083 (CI 0.586 to 0.831) and 0.704± 0.081 (CI 0.568 to 0.817), respectively.
CONCLUSION: VTE can be seen in approximately one fourth of patients with CTD-ILD or IIP and the Wells score and the revised Geneva score can be used for categorising PE risk.
Copyright © 2014 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Interstitial lung disease; Pulmonary embolism; Revised Geneva scores; Venous thromboembolism; Wells score

Mesh:

Substances:

Year:  2014        PMID: 24685075     DOI: 10.1016/j.hlc.2014.02.014

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  7 in total

Review 1.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

Review 2.  Comparison of the Wells score with the revised Geneva score for assessing suspected pulmonary embolism: a systematic review and meta-analysis.

Authors:  Jun-Hua Shen; Hong-Lin Chen; Jian-Rong Chen; Jia-Li Xing; Peng Gu; Bao-Feng Zhu
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

3.  The Prevalence of Pulmonary Embolism in Patients With Interstitial Lung Disease: A Cross-Sectional Retrospective Study.

Authors:  Rahmah Alsilmi
Journal:  Cureus       Date:  2022-03-11

4.  Value of D-dimer in predicting various clinical outcomes following community-acquired pneumonia: A network meta-analysis.

Authors:  Jiawen Li; Kaiyu Zhou; Hongyu Duan; Peng Yue; Xiaolan Zheng; Lei Liu; Hongyu Liao; Jinlin Wu; Jinhui Li; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

Review 5.  Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.

Authors:  Sylvia M Nikkho; Manuel J Richter; Eric Shen; Steven H Abman; Katerina Antoniou; Jonathan Chung; Peter Fernandes; Paul Hassoun; Howard M Lazarus; Horst Olschewski; Lucilla Piccari; Mitchell Psotka; Rajan Saggar; Oksana A Shlobin; Norman Stockbridge; Patrizio Vitulo; Carmine Dario Vizza; Stephen J Wort; Steven D Nathan
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

Review 6.  Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns.

Authors:  George Keramidas; Konstantinos I Gourgoulianis; Ourania S Kotsiou
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

Review 7.  Therapeutic Approach to Adult Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Mary E Strek
Journal:  Chest       Date:  2016-08-10       Impact factor: 9.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.